Thomas Evans
Chief Tech/Sci/R&D Officer at Vaccitech (UK) Ltd.
Profile
Thomas G.
Evans is currently the Chief Scientific Officer at Vaccitech (UK) Ltd.
He previously served as the Chief Executive Officer at Aeras Global TB Vaccine Foundation from 2013 to 2016.
He also held the position of Chief Medical Officer at Vical, Inc. Additionally, he worked as an Associate Professor at the University of Rochester and as the Chief-Infectious Diseases & Professor at the University of California, Davis.
From 2005 to 2008, he was the Global Head-Infectious Diseases at Novartis Institutes for Biomedical Research, Inc. Dr. Evans is also currently the Chief Scientific Officer at Barinthus Biotherapeutics Plc, a position he has held since 2019.
He holds a doctorate degree from the University of Virginia and an undergraduate degree from Williams College.
Thomas Evans active positions
| Companies | Position | Start |
|---|---|---|
Vaccitech (UK) Ltd.
 Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Chief Tech/Sci/R&D Officer | 2019-08-27 |
Former positions of Thomas Evans
| Companies | Position | End |
|---|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2023-01-29 |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Chief Executive Officer | 2016-04-30 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2008-08-31 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
| University of California, Davis | Corporate Officer/Principal | - |
Training of Thomas Evans
| University of Virginia | Doctorate Degree |
| Williams College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Health Technology |
| Private companies | 4 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Thomas Evans
